IBIO: financial statements from SEC — TradeAlmanac

IBIO

iBio, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Revenue	—	0	100,000	0	200,000	0
Research and development	3m	4m	4m	2m	2m	1m
Selling, general and administrative	5m	5m	3m	3m	3m	3m
Operating expenses	8m	9m	6m	5m	5m	4m
Operating income	−8m	−9m	−6m	−5m	−4m	−4m
Net income	−8m	−9m	−6m	−5m	−4m	−4m
Earnings per share	−0.06	−0.09	−0.11	−0.49	−0.48	−0.46
Earnings per share, diluted	−0.06	−0.09	−0.11	−0.49	−0.48	−0.46
Weighted average shares	120m	99m	53m	10m	9m	9m
Weighted average shares, diluted	120m	99m	53m	10m	9m	9m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	48m	29m	28m	9m	5m	7m	11m	14m
Receivables	—	—

Cash flow

Metric	Sep 30, 2025	Sep 30, 2024
Operating cash flow	−6m	−4m
Depreciation and amortisation	123,000	120,000
Share-based compensation	323,000	415,000
Capital expenditure	32,000	0
Investing cash flow	−21m	713,000
Financing cash flow	47m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)